Ollevr | MNNT Wae1th (CPA)
113 posts



One stock I'm mulling over a lot lately is $AEHR. It's starting to look more like a necessity in the AI buildout and less like a speculative bet. As more and more bottlenecks appear, more ways of chips "failing" increases... i.e. thermal, packaging, interconnect failures. Thermal is the biggest one though. More advanced chips means more heat which means more likely chips melt down. This is where $AEHR comes in. They stress test ever chip. But here's where the numbers get interesting: Currently analysts are estimating $82M in revenue in FY27. You can make quite a reasonable case that $82M is VERY conservative by just replacing what management has said and doing some simple numbers on bookings and capacity. 1. Management's own $60-80M 2H FY26 booking guide vs $25-$30M revenue all but guarantees a large backlog entering FY27. 2. Majority of these bookings are high value AI wafer and package level burn in, not low margin legacy orders. 3. Sonoma AI ASIC forecasts starting to ship in Q1 FY27. 4. The $14M AI processor order, silicon photonics follow on, and rising early Q3 bookings is already underway. Put simply, I'd argue if $AEHR actually books anywhere near $60-80M in 2H FY26 and converts even a normal portion of that... $82M seems like a bearish forecast. The question is then whether +80% expected growth in FY27 warrants a 17x sales multiple... and I think it does. I think it's time for $AEHR to rerate now in the midst of this CapEx cycle.



Tough to be exact but here's some back of the paper napkin math showing why $TEM at $9.2B MC is cheap: The Data & Applications segment alone is generating ~$400M in revenue in FY26. That's based on the current 25/75 split in revenue between Data & Applications and Diagnostics and total FY26 guidance of $1.6B. That Data & Application segment is growing ~40% YoY with 73% gross margins. That's in line with a solid SaaS company that would normally trade ~12-15x sales based on that growth. $400M * 12x = $4.8B $400M * 15x = $6B And then the Diagnostics segment is producing roughly $1.2B in revenue. $GH trades at 13x sales and is probably the fairest comp? So let's give $TEM's segment here a conservative 10x multiple: $1.2B * 10x = $12B That's $12B + $6B = $18B MC with how the business looks today. Current MC: $9.2B

If you had a choice between instantly receiving £50,000 or a 50% chance to win £1m, which would you pick? £50,000: 73% 50/50 chance of winning £1m: 21%


